Context Therapeutics Inc. CNTX
0.35
(0.02)
(5.41%)
as of 25 Sep
- Market cap
- $34.1M
- P/E
- 0.0×
Follow CNTX
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
— | 0.01 | 0.03 | 16.90 | 11.80 | 3.83 | 35.62 | 8.52 |
Net Debt/EBITDA |
— | (4.02) | (2.18) | 4.72 | 2.31 | 0.58 | 3.16 | 1.66 |
Debt/Assets |
0.00% | 7,986.44% | 1,262.21% | 0.00% | 0.15% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | (0.92) | (0.35) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | 0.44 | (0.97) | 0.84 | 0.91 | 0.88 | 0.54 | 0.73 |
Capex/Depreciation |
— | — | — | — | (3.96) | 0.00 | (0.67) | (2.08) |
Interest Coverage |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | 31.23% | (5.24%) | (66.71%) | (35.74%) | (102.79%) | (49.89%) | (46.39%) | |
| — | (4,668.52%) | 289.12% | (40.40%) | (33.24%) | (88.71%) | (46.81%) | (43.36%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (2,235.80%) | 0.00% |
Return on Tangible Assets |
— | 26.75% | (11.58%) | (21.68%) | (42.79%) | (201.87%) | (28.08%) | (59.84%) |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
— | (0.26) | (2.97) | (3.10) | (0.85) | (1.32) | (0.25) | (0.28) |
Cash per Share |
— | 0.02 | 0.84 | 17.51 | 2.22 | 0.91 | 1.62 | 0.69 |
Shareholders Equity per Share |
— | (2.17) | (48.62) | 17.03 | 2.18 | 0.74 | 1.63 | 0.64 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (2.17) | (48.62) | 17.03 | 2.18 | 0.74 | 1.63 | 0.64 |
Free Cash Flow |
— | (2.84) | (1.03) | (8.80) | (13.59) | (21.05) | (14.56) | (26.42) |
Working Capital |
— | (23.87) | (9.25) | 48.22 | 34.65 | 11.86 | 95.15 | 60.33 |
Capital Expenditures |
— | — | — | — | (0.04) | — | (0.01) | (0.03) |
Net Current Asset Value |
— | (23.87) | (17.09) | 48.22 | 34.65 | 11.86 | 95.04 | 60.33 |
| Other line items | ||||||||
Quick Ratio |
— | 0.01 | 0.03 | 16.36 | 11.07 | 3.45 | 34.36 | 8.23 |
Depreciation/Fixed assets |
— | — | — | — | 0.34 | 0.77 | 0.91 | 0.55 |
Cash ROIC |
— | 160.66% | 9.64% | (8.99%) | (19.31%) | (80.02%) | (7.68%) | (20.89%) |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | 0.00 | — | — | — |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | 0.00 | — | — | — |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | (0.26) | (2.97) | (3.10) | (0.85) | (1.32) | (0.25) | (0.28) |
Capex per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Payables |
— | 2.39 | 2.39 | 2.27 | 1.38 | 1.66 | 1.92 | 1.99 |
Average Assets |
— | 0.14 | 0.37 | 25.89 | 44.64 | 27.01 | 57.09 | 83.31 |
Average Common Equity |
— | (20.44) | (20.44) | 15.68 | 41.52 | 23.31 | 53.57 | 77.87 |
Capex to Sales |
— | — | — | — | 0.00 | — | 0.00 | 0.00 |
Net Profit Margin |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates